In a phase II B, single‐center, randomized, controlled trial of G‐CSF treatment, Timothy J England found a trend toward reduced changes from baseline in MRI ischemic lesion volume, suggesting that subacute administration of G‐CSF is safe and that CD34(+) iron labeling in patients with ischemic stroke is feasible.38 This evidence concerns the gene CD34 and ischemic stroke.